Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study.
Author(s): Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC
Publication: Am J Kidney Dis, 2008, Vol. 51, Page 987-95
PubMed ID: 18430500 PubMed Review Paper? No
Purpose of Paper
Conclusion of Paper
The purpose of this study was to determine the effects of anticoagulant, assay type and storage on the measurement of PTH in blood specimens.
Summary of Findings:
Anticoagulant and assay type significantly affected the measured PTH variability (both p<0.001), but storage did not. While interindividual variability accounted for 96.8% of the variability, 2.5% of the variability was attributed to kit and 0.7% to anticoagulant. Citrated plasma consistently had lower levels of PTH than EDTA plasma and serum. Importantly, the differences in anticoagulant and kit type led to different Kidney Disease Outcomes Quality Initiative (KDOQI) classifications.
- Diabetes Type 2
- Not specified
Analyte Technology Platform Peptide Clinical chemistry/auto analyzer
Classification Pre-analytical Factor Value(s) Biospecimen Aliquots and Components Blood and blood products Plasma
Storage Time at room temperature 0 h
Clinical chemistry/auto analyzer Specific Technology platform Roche Elecsys
Bayer Advia Centaur
Biospecimen Acquisition Anticoagulant EDTA